Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome

This is a multi-centre, observational, non-comparative, retrospective cohort study designed to evaluate the long-term safety and effectiveness of osilodrostat in non-CD CS patients. Patients treated with oral osilodrostat regardless of the duration of their treatment will be followed retrospectively for up to 36 months after initiating osilodrostat.

Inclusion Criteria:Male and female patients ≥18 years old with diagnosis of CS, except for CD (i.e., an aetiology of adrenal adenoma, adrenocortical carcinoma, adrenal hyperplasia, or ectopic adrenocorticotropic hormone secretion). Patients should have a contemporaneously documented diagnosis of CS as per effective guidelines.Patients treated with osilodrostat between April 2019 and study start date as part of ATU programme or commercialisation.Exclusion Criteria:Patients who participated in a clinical trial anytime during the study period.Patients with Pseudo-Cushing's syndrome, cyclic CS, or iatrogenic CS.